Abstract: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41% of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Abstract: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Abstract: A foam is described for injection treatment of varicose veins. The foam comprises a sclerosant liquid, e.g. polidocanol solution, and a gas. The gas comprises xenon, optionally together with at least one other physiologically acceptable gas which is readily absorbed in the body or blood of a patient. The gas comprises only a minimal amount of gaseous nitrogen, between 0.0001% and 0.8%.